It is likely that SBP is most predictive of cardiovascular outcomes, however, DBP may be analysed in future work
The response from many of those employers has been swift: Blue Cross Blue Shield of Massachusetts dropped GLP-1 coverage for obesity treatment for employers with fewer than 100 employees at the start of 2026 Harvard Pilgrim Health Care and Blue Cross Blue Shield of Michigan both dropped weight-loss GLP-1 coverage in 2026 HCA Healthcare one of the countrys largest hospital systems notified employees that its GLP-1 coverage was ending after usage surged 90% in a single year, directing workers instead toward manufacturer cash-pay programs Several other employers have stopped short of elimination but have tightened requirements dramatically restricting coverage only to patients with a formal diabetes diagnosis and removing access for patients using GLP-1s for weight management alone. Why Are Employers Cutting This Coverage Now
Stokes CS, Gluud LL, Casper M, Lammert F
glycerin and beta-glucan, which attract and bind water to the skin
Hansson L, Zanchetti A, Carruthers SG, Dahlf B, Elmfeldt D, Julius S, et al